Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Blood Cancer, Infectious Disease, Lymphoma, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Immunology / Infectious Diseases, Oncology |
| Healthy: | No |
| Age Range: | Any - 65 |
| Updated: | 5/5/2014 |
| Start Date: | January 1997 |
The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral
blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the
patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
from a donor are infused into the patient they may help the patient's bone marrow make stem
cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem
cell transplant in treating patients with hematologic cancer.
blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the
patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
from a donor are infused into the patient they may help the patient's bone marrow make stem
cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem
cell transplant in treating patients with hematologic cancer.
OBJECTIVES:
- Determine the efficacy and safety of allogeneic peripheral blood stem cell
transplantation in achieving engraftment in patients with hematologic malignancy.
- Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity,
relapse, graft-versus-host disease, and survival of patients treated with this regimen.
OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host
disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood
stem cell transplantation on day 0.
Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months.
PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
- Determine the efficacy and safety of allogeneic peripheral blood stem cell
transplantation in achieving engraftment in patients with hematologic malignancy.
- Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity,
relapse, graft-versus-host disease, and survival of patients treated with this regimen.
OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host
disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood
stem cell transplantation on day 0.
Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months.
PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
DISEASE CHARACTERISTICS:
- Diagnosis of one of the following:
- Chronic myelogenous leukemia
- Philadelphia chromosome-positive OR
- Molecular evidence of bcr/abl gene rearrangement
- Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses,
myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia,
paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia
- Confirmed by cytochemistry, immunophenotyping, and/or chromosomal
abnormalities
- Multiple myeloma
- Hereditary immunodeficiency disorders
- Confirmed by immunologic determination
- Sickle cell anemia or beta-thalassemia
- Confirmed by hemoglobin electrophoresis
- Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic
leukodystrophy)
- Confirmed by metabolic testing
- Other non-malignant conditions
- Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation
PATIENT CHARACTERISTICS:
Age:
- 65 and under
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
We found this trial at
1
site
701 West 168th Street
New York, New York 10032
New York, New York 10032
(212) 851-4680
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center The Herbert Irving Comprehensive Cancer...
Click here to add this to my saved trials
